SCHEMBL3539336

SCHEMBL3539336

CCN(CC1CCCC1)c1cc2c(cc1C=O)CCC2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ALDH1A3 P47895 1/20 0.33
ALDH1A1 P00352 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
ADH1C P00326 1/20 0.31
ADH1A P07327 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
CNR1 P21554 1/20 0.31
CNR2 P34972 1/20 0.31
ALDH3A1 P30838 1/20 0.30
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3545615 0.97 CNR1 (0.33) NPC1CYP1A2CYP3A4CYP2D6HPGD
SCHEMBL3041869 0.83 ALDH1A1 (0.35) HPGDALDH1A3ALDH1A1L3MBTL1ADH1C
SCHEMBL3041872 0.78 CNR1 (0.40) NPC1RAB9AALDH1A3ALDH1A1L3MBTL1
SCHEMBL3043965 0.77 PSEN1 (0.39) ALDH1A3ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3046946 0.77 ALDH1A1 (0.39) NPC1HPGDRAB9ASMN1; SMN2ALDH1A3
SCHEMBL3043051 0.77 ALDH1A3 (0.40) NPC1RAB9AALDH1A3ALDH1A1L3MBTL1
SCHEMBL3036495 0.77 GRIA2 (0.38) NPC1RAB9ASMN1; SMN2ALDH1A3ALDH1A1
SCHEMBL3043756 0.77 ALDH1A3 (0.43) NPC1RAB9AALDH1A3ALDH1A1L3MBTL1
SCHEMBL3043759 0.76 SRC (0.38) ALDH1A3ALDH1A1L3MBTL1ADH1CADH1A
SCHEMBL3039488 0.75 ALDH1A1 (0.46) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807701-B2 Dibenzylamine compounds and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2010-10-05 US disclosed
US-20080146620-A1 Dibenzylamine Compounds and Pharmaceutical Use Thereof JAPAN TOBACCO INC. (JP) 2008-06-19 US disclosed
US-7332514-B2 Dibenzylamine compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2008-02-19 US disclosed
EP-1829858-A2 Dibenzylamine compounds and pharmaceutical use thereof Japan Tobacco, Inc. (JP) 2007-09-05 EP disclosed
EP-1533292-B1 DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC (JP) 2007-02-14 EP disclosed
EP-1533292-A1 DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2005-05-25 EP disclosed
US-20050059810-A1 Dibenzylamine compound and medicinal use thereof JAPAN TOBACCO INC 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059810-A1 Dibenzylamine compound and medicinal use thereof CETP, CES1, APOB NPC1 5/4885CYP1A2 873/4885CYP3A4 448/4885
US-20080146620-A1 Dibenzylamine Compounds and Pharmaceutical Use Thereof CETP, PCSK9, CES1 NPC1 5/4885CYP1A2 750/4885CYP3A4 356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.